ESTA vs MBOT
ESTA: A global medical technology company revolutionizing the breast aesthetics and reconstruction market through its proprietary, safety-focused Motiva Implants and minimally invasive surgical platforms. MBOT: Microbot Medical is an early-stage medical device company developing next-generation robotic endoluminal surgical systems for minimally invasive interventional procedures.
Side-by-side fundamentals
| Metric | ESTA | MBOT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $93.87 | $1.77 | |
| Market cap as of 2026-07-23 | $2.8B | $119M | |
| Net margin as of 2026-07-23 | -19.1% | -3496.2% | ESTA higher |
| Gross margin as of 2026-07-23 | +70.1% | +1.9% | ESTA higher |
| Operating margin as of 2026-07-23 | -12.4% | -4114.3% | ESTA higher |
| ROE as of 2026-07-23 | -225.9% | -21.8% | MBOT higher |
| ROA as of 2026-07-23 | -12.7% | -20.7% | ESTA higher |
| Debt / equity as of 2026-07-23 | 17.58 | 0.00 | MBOT lower |
| Revenue growth (YoY) as of 2026-07-23 | +34.9% | -50.0% | ESTA higher |
| Revenue CAGR (3y) SEC XBRL | +9.3% | -56.0% | ESTA higher |
| Beta as of 2026-07-23 | 1.10 | 1.04 | |
| 1-year return as of 2026-07-22 close | +115.9% | -30.0% | ESTA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.